IDev Technologies, Inc. Gains CE Mark Approval for New Nitinol Stent in Peripheral Vascular Disease

May 03, 2006, 01:00 ET from IDev Technologies, Inc.

    HOUSTON, May 3 /PRNewswire/ -- IDev Technologies, Inc., an emerging
 leader in the development and marketing of minimally invasive stent systems
 for the treatment of peripheral vascular and non-vascular diseases, today
 announces CE Mark approval for use of its stent in Europe.
     Specifically, the CE Mark approval is in respect to the design,
 development and manufacture of devices for removal of inadvertently
 dislodged or misplaced objects from peripheral body vasculature, for
 palliative treatment of Biliary strictures produced by malignant neoplasms
 and for use in peripheral vasculature for failed PTA.
     Thomas M. Tully, Chairman and CEO commented, "European approval for the
 IDev Technologies, Inc. stent is the first critical step toward the
 commercialization of this novel technology worldwide. The company is
 initially preparing a limited distribution strategy to elite interventional
 centers throughout Europe. These elite centers will be the first to offer
 the innovative IDev Technologies, Inc. stent to over 2.5 million patients
 who suffer from Critical Limb Ischemia in the developed world."
     About IDev Technologies, Inc.
     IDev Technologies, Inc. ("IDEV") is an Innovator and Developer of next
 generation minimally invasive medical devices for the treatment of
 peripheral vascular disease (PVD). PVD is currently treated by
 interventional radiologists, vascular surgeons, and cardiologists. The
 Company has recently received a CE Mark approval for use of the stent in
 peripheral vascular and non-vascular applications and is preparing to
 launch the product in Europe shortly. The IDev Technologies, Inc. stent is
 a unique device that is a self- expandable nitinol stent with significant
 radial force that is resistant to kinking, crushing and fracture potential.
 Additionally, the unique delivery system allows for precise placement and
 repositionability prior to deployment. These features represent a
 significant advance over existing stent technologies for peripheral
 vascular applications.

SOURCE IDev Technologies, Inc.